The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
INAVO120 phase 3 trial: Subgroup analyses of Asian patients (pts) with PIK3CA-mutated (mut), hormone receptor-positive, HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).
 
Yoon Sim Yap
Honoraria - AstraZeneca; Daiichi Sankyo; DKSH; Gilead Sciences; Menarini; Novartis; Olema Oncology; Pfizer; Puma Biotechnology; Roche
Research Funding - Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; DKSH; Novartis; Roche
Other Relationship - F. Hoffmann LaRoche
 
Huiping Li
No Relationships to Disclose
 
Qingyuan Zhang
Other Relationship - Research funding in the form of third-party medical writing assistance, furnished by Kalina Boytcheva, MSc, of Nucleus Global, an Inizio Company, from F. Hoffmann-La Roche Ltd
 
Patrapim Sunpaweravong
Other Relationship - Research funding in the form of third-party medical writing assistance, furnished by Kalina Boytcheva, MSc, of Nucleus Global, an Inizio Company, from F. Hoffmann-La Roche Ltd
 
Roland Leung
Travel, Accommodations, Expenses - Roche/Genentech
 
Chayanee Samdaengpan
No Relationships to Disclose
 
Chi-Feng Chung
Consulting or Advisory Role - AstraZeneca; Daichi Sankyo; EirGenix; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/UCB Japan; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
Xiaojia Wang
Other Relationship - Research funding in the form of third-party medical writing assistance, furnished by Kalina Boytcheva, MSc, of Nucleus Global, an Inizio Company, from F. Hoffmann-La Roche Ltd
 
Kyung Hae Jung
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bixink; Celgene; Daewoong Pharmaceutical; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Eisai; Everest Medicine; Gilead Sciences; ImmuneOncia; Merck; MSD; Novartis; Novartis; Novartis; Novartis; Pfizer; Roche; Roche; Takeda
 
Hooi Lay Teh
Employment - Gleneagles Hospital Johor
Other Relationship - Research funding in the form of third-party medical writing assistance, furnished by Kalina Boytcheva, MSc, of Nucleus Global, an Inizio Company, from F. Hoffmann-La Roche Ltd
 
Ling-Ming Tseng
Other Relationship - Research funding in the form of third-party medical writing assistance, furnished by Kalina Boytcheva, MSc, of Nucleus Global, an Inizio Company, from F. Hoffmann-La Roche Ltd
 
Neville Chua
Employment - Roche
Stock and Other Ownership Interests - Roche
Other Relationship - Research funding in the form of third-party medical writing assistance, furnished by Kalina Boytcheva, MSc, of Nucleus Global, an Inizio Company, from F. Hoffmann-La Roche Ltd
 
Yanling Jin
Employment - Roche
Stock and Other Ownership Interests - Roche
Other Relationship - Research funding in the form of third-party medical writing assistance, furnished by Kalina Boytcheva, MSc, of Nucleus Global, an Inizio Company, from F. Hoffmann-La Roche Ltd
 
Tiffany Clark
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Other Relationship - Research funding in the form of third-party medical writing assistance, furnished by Kalina Boytcheva, MSc, of Nucleus Global, an Inizio Company, from F. Hoffmann-La Roche Ltd
 
Seock-Ah Im
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; SK Biopharmaceutical
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
(OPTIONAL) Uncompensated Relationships - Roche